AXSOME THERAPEUTICS I

Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

03 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

29 Sep 2022 07:28:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

21 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

14 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

08 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

07 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

01 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

19 Aug 2022 06:45:03 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

28 Jul 2022 07:00:02 By Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

28 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event

22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

06 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

02 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

31 May 2022 07:39:37 By Nasdaq GlobeNewswire

Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

09 May 2022 08:57:19 By Nasdaq GlobeNewswire

Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience

28 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in the 1st Annual Needham Virtual Neuroscience Forum

11 Mar 2022 07:00:00 By Nasdaq GlobeNewswire